SHARE ISSUE
Based on the power of attorney granted at the annual general meetings of NattoPharma ASA ("NattoPharma" or "Company") on June 25, 2015 and May 20, 2016, the Board of Directors of NattoPharma has in board proceedings June 24th, 2016 approved a share issue of 305 000 new shares, each with a face value of NOK 3 per share.
The share issue will be completed through issuance of new shares to leading employees in accordance with the company’s incentive program according to the following plan;
| Name | Position / Function | Granted shares | Shares prior to share issue | Shares after share issue |
| Daniel H. Rosenbaum | CEO | 100.000 | 0 | 100.000 |
| Kjetil Ramsøy | CFO | 100.000 | 0 | 100.000 |
| Eric Anderson | VP Sales & Marketing | 50.000 | 0 | 50.000 |
| Rudi de Man | VP Sales Europe & Asia | 30.000 | 0 | 30.000 |
| William Sommer | VP Global Development and Regulatory | 25.000 | 0 | 25.000 |
Price to be paid for each share is NOK 3 per share. The share issue is expected to be completed within July 31st, 2016.
As a result, the share capital will be increased by NOK 915 000. The Company’s new share capital after the share issue will be NOK 52 334 799 divided into 17 444 933 shares, each with a face value of NOK 3.
* * *
For more information, please contact:
Kjetil Ramsøy, Chief Financial Officer
E-mail: kjetil.ramsoy@nattopharma.com
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Tags: